STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!